nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.12.2012 | AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

An Update on Stem Cell Transplantation in Autoimmune Rheumatologic Disorders

verfasst von: Sheryl Mascarenhas, Belinda Avalos, Stacy P. Ardoin

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Stem cell transplant (SCT) has long been the standard of care for several hematologic, immunodeficient, and oncologic disorders. Recently, SCT has become an increasingly utilized therapy for refractory autoimmune rheumatologic disorders (ARDs). The efficacy of SCT in ARDs has been attributed to resetting an aberrant immune system either through direct immune replacement with hematopoietic stem cells or through immunomodulation with mesenchymal stem cells. Among ARDs, refractory systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are the most common indications for SCT. SCT has also been used in refractory rheumatoid arthritis, inflammatory myopathies, antiphospholipid syndrome, granulomatosis with polyangiitis, and pediatric ARDs. Complete responses have been reported in approximately 30 % of patients in all disease categories. Transplant-related mortality, however, remains a concern. Future large multi-center prospective randomized clinical trials will help to better define the specific role of SCT in the treatment of patients with ARDs.

Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S48–56.PubMedCrossRef

Hönig M, Schulz A, Friedrich W. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Klin Padiatr. 2011;223(6):320–5.PubMedCrossRef

Kiem HP, Jerome KR, Deeks SG, et al. Hematopoietic-stem-cell-based gene therapy for HIV disease. Cell Stem Cell. 2012;10(2):137–47.PubMedCrossRef

Chang JW, Hung SP, Wu HH, et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant. 2011;20(2):245–57.PubMedCrossRef

DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III Prosepective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared with Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27(28):4767–73.PubMedCrossRef

Moore J, Brooks P, Milliken S, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hematopoietic stem cell transplantation for severe refractory rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2301–9.PubMedCrossRef

Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276(5309):71–4.PubMedCrossRef

Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.PubMedCrossRef

Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393–5.PubMedCrossRef

10.

Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol. 2007;180:45–66.PubMedCrossRef

11.

Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147–53.PubMedCrossRef

12.

Li HW, Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol. 2012;12(6):403–16.PubMedCrossRef

13.

Hénon PH, Sovalat H, Bourderont D. Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34 + CD38- cells as predictive tool for hematopoietic engraftment. J Biol Regul Homeost Agents. 2001;15(1):62–7.PubMed

14.

De Kleer I, Vasstert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4 + CD25+ immune regulatory network. Blood. 2006;107(4):1696–702.PubMedCrossRef

15.

Roord ST, de Jager W, Boon L, et al. Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4 + CD25 + Foxp3+ regulatory T cells. Blood. 2008;111(10):5233–41.PubMedCrossRef

16.

Wang D, Zhang H, Cao M, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70(7):1285–8.PubMedCrossRef

17.

Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025–32.PubMedCrossRef

18.

Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419–27.PubMedCrossRef

19.

Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007;262:509–25.PubMedCrossRef

20.

Szodoray P, Varoczy L, Papp G, et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand J Rheumatol. 2012;41(2):110–5.PubMedCrossRef

21.

Steingrimsdottir H, Gruber A, Björkholm M, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica. 2000;85(8):832–8.PubMed

22.

Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine. 2011;56(3):544–9.PubMedCrossRef

23.

Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications in targeted therapy. J Rheumatol. 2012;39(6):1120–4.PubMedCrossRef

24.

Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992;166(3):255–63.PubMedCrossRef

25.

Hu H, Stein-Streilein J. Hapten-immune pulmonary interstitial fibrosis (HIPIF) in mice requires both CD4+ and CD8+ T lymphocytes. J Leukoc Biol. 1993;54(5):414–22.PubMed

26.

Rosa SB, Voltarelli JC, Chies JA, et al. The use of stem cells for the treatment of autoimmune diseases. Braz J Med Biol Res. 2007;40(12):1579–97.PubMedCrossRef

27.

•• Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol. 2011;23(6):519–29. Excellent overview of HSCT use in SSc.PubMedCrossRef

28.

Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant. 2007;40:549–55.PubMedCrossRef

29.

McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002;100:1602–10.PubMed

30.

Marjanovic Z, J. Snowden, M. Badoglio, et al.: Long-term outcomes of autologous haematopoietic stem cell transplantation in severe autoimmune diseases: an extended analysis of the EBMT database 1996–2011. Presented at the 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT). Geneva, Switzerland; April 1–4, 2012.

31.

• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haematopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. 2011;378(9790):498–506. First randomized controlled trial regarding HSCT use in systemic sclerosis.PubMedCrossRef

32.

Henes JC, Schmalzing M, Vogel W, et al. Optimization of autologous stem cell transplantation for systemic sclerosis—a single-center long term experience in 26 patients with severe organ manifestations. J Rheumatol. 2012;39(2):269–75.PubMedCrossRef

33.

•• Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program. 2011;2011:280–4. Excellent review of SCT use in autoimmune diseases.PubMedCrossRef

34.

Scleroderma clinical trials: Astis Study. Available at http://www.sclero.org/medical/treatments/clinical-trials/current/astis/a-to-z.html. Accessed June 2012.

35.

Autologous stem cell transplantation international scleroderma(ASTIS) trial. Available at http://www.controlled-trials.com/ISRCTN54371254. Accessed June 2012.

36.

van Laar JM, Farge D, Sont JK, et al.: The ASTIS Trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. [abstract LB0002]. Presented at EULAR. Berlin, Germany: June 6–9, 2012.

37.

Musculoskeletal report: High-Dose Immune Suppression With or Without Stem Cell Transplants For Systemic Sclerosis. Available at http://www.mskreport.com/articles.cfm?articleID=1084. Accessed June 2012.

38.

Illei GG, Cervera R, Burt RK, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(12):2071–4.PubMedCrossRef

39.

Song X, Lv HY, Sun LX, et al. Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients. Transplant Proc. 2011;43(5):1924–7.PubMedCrossRef

40.

Mok CC, Ying, KY, Ng WL, et al.: Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide. Am J Med 2006, 119(4): 355. e25-e33.

41.

Meng J, Wang J, Liang W, et al. Long-term remission after successful pregnancy in autologous peripheral blood stem cell transplanted system lupus erythematosus patients. Rheumatol Int. 2011;31(5):691–4.PubMedCrossRef

42.

Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903–11.PubMedCrossRef

43.

Gonzalez-Rey E, Gonzalez MA, Varela N, et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241–8.PubMedCrossRef

44.

Wu CC, Wu TC, Liu FL, et al. TNF-α inhibitor reverse the effects of human umbilical cord-derived stem cells on experimental arthritis by increasing immunosuppression. Cell Immunol. 2012;273(1):30–40.PubMedCrossRef

45.

Snowden JA, Passweg J, Moore JJ, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol. 2004;31(3):482–8.PubMed

46.

Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010;12(6):R210.PubMedCrossRef

47.

Park MJ, Park HS, Cho ML, et al. Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum. 2011;63(6):1668–80.PubMedCrossRef

48.

Dalakas MC. Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev. 2012;11(3):203–6.PubMedCrossRef

49.

Mahil S, Marks D, McComrack M, et al. Dermatomyositis. Br J Hosp Med (Lond). 2012;73(2):C18–22.

50.

Ra JC, Kang SK, Shin IS, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. J Transl Med. 2011;9:181.PubMed

51.

Owaidah TM, Maghrabi K, Elkarouri MA, et al. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature. Bone Marrow Transplant. 2011;46(4):597–600.PubMedCrossRef

52.

Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol. 2008;14(6):359–60.PubMedCrossRef

53.

Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106(8):2700–9.PubMedCrossRef

54.

Schilder AM. Wegener’s Granulomatosis vasculitis and granuloma. Autoimmun Rev. 2010;9(7):483–7.PubMedCrossRef

55.

Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener’s). Curr Treat Options Cardiovasc Med. 2012;14(2):164–76.PubMedCrossRef

56.

Daikeler T, Erley C, Mohren M, et al. Fever and increasing cANCA titre after kidney and autologous stem cell transplantation for Wegener’s Granulomatosis. Ann Rheum Dis. 2005;64(4):646–7.PubMedCrossRef

57.

Kunitomi A, Ishikawa T, Tajima K, et al. Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia. Int J Hematol. 2006;83(3):262–5.PubMedCrossRef

58.

Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis. 2006;65(4):508–14.PubMedCrossRef

59.

Daikeler T, Kötter I, Bocelli Tyndall C, et al. Haematopoietic stem cell transplantation for vasculitis including Behcet’s disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann Rheum Dis. 2007;66(2):202–7.PubMedCrossRef

60.

Statkute L, Oyama Y, Barr WG, et al. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis. 2008;67(9):991–7.PubMed

61.

Bornhäuser M, Aringer M, Theide C. Mixed lymphohematopoietic chimerism and response in Wegener’s granulomatosis. N Engl J Med. 2010;362(25):2431–2.PubMedCrossRef

62.

De Kleer IM, Brinkman DM, Ferster A, et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis. 2004;63(10):1318–26.PubMedCrossRef

63.

Brinkman DM, de Kleer IM, ten Cate R, et al. Autologous stem cell transplantation in children with severe progressive systemic or polyarticular idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum. 2007;56(7):2410–21.PubMedCrossRef

64.

Rabusin M, Andolina M, Maximova N, et al. Haematopoietic SCT in autoimmune diseases in children: rational and new perspectives. Bone Marrow Transplant. 2008;41 suppl 2:S96–9.PubMedCrossRef

65.

Chen J, Wang Y, Kunkel G, et al. Use of CD34+ autologous stem cell transplantation in the treatment of children with refractory systemic lupus erythematosus. Clin Rheumtol. 2005;24(5):464–8. 2 patients.CrossRef

66.

Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168–76.PubMedCrossRef

67.

Krauss AC, Kamani NR. Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go. Bone Marrow Transplant. 2009;44:137–43.PubMedCrossRef

68.

Wulffraat NM, van Rooijen EM, Tewarie R, et al. Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis. Autoimmunity. 2008;41(8):632–8.PubMedCrossRef

69.

Lawitschka A, Peters C, Seidel MG, et al. Long-term remission in pediatric Wegener granulomatosis following allo-SCT after reduced intensity conditioning. Bone Marrow Transplant. 2011;46(3):462–3.PubMedCrossRef

70.

Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis. 2004;63(8):974–81.PubMedCrossRef

71.

Swart JF, Lindemans CA, van Royen A, et al. Changing winds in refractory autoimmune disease in children: clearing the road for tolerance with cellular therapies. Curr Opin Rheumatol. 2012;24(3):267–73.PubMedCrossRef

72.

Hügle T, van Laar JM. Stem cell transplantation for rheumatic autoimmune diseases. Arthritis Res Ther. 2008;10(5):217.PubMedCrossRef

73.

Blazer BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443–58.CrossRef

74.

Pasquini MC, Wang Z, Horowitz MM, et al. report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transplant. 2010;2010:87–105.

75.

Stamatović D, Balint B, Tukić L, et al. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies. Vojnosanit Pregl. 2011;68(12):1026–32.PubMedCrossRef

76.

Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune disease, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004;34(10):877–81.PubMedCrossRef

77.

Burt RK, Shah SJ, Gheorghiade M, et al. Hematopoietic stem cell transplantation for systemic sclerosis: if you are confused, remember: “it is a matter of the heart”. J Rheumatol. 2012;39(2):206–9.PubMedCrossRef

78.

Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev. 2008;7:198–203.PubMedCrossRef

79.

Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for anautoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118:1693–8.PubMedCrossRef

80.

Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol. 2005;141(1):1–9.PubMedCrossRef

81.

Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(5):359–65.PubMedCrossRef

82.

Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997;19(7):643–5.PubMedCrossRef

83.

Scleroderma Cyclophosphamide or Transplantation Study (SCOT). Available at. https://www.fbo.gov/index?s=opportunity&mode=form&id=e3a055606954c423b4a4606326f96081&tab=core&_cview=0. Accessed June 2012.

84.

Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot study. Ann Rheum Dis. 2010;69(8):1423–9.PubMedCrossRef

85.

Sun L, Akiyama K, Zhang H, et al. Mesenchymal Stem Cell Transplantation Reverses Multi-Organ Dysfunction in Systemic Lupus Erythematosus Mice and Humans. Stem Cells. 2009;27(6):1421–32.PubMedCrossRef

86.

Abinun M, Flood TJ, Cant AJ, et al. Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000–2007). Mol Immunol. 2009;47(1):46–51.PubMedCrossRef

87.

Daikeler T, Hügle T, Farge D, et al. Allogenic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant. 2009;44(1):27–33.PubMedCrossRef

88.

Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214–23.PubMedCrossRef

89.

Nevskaya T, Ananieva L, Bykovskaia S, et al. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford). 2009;48(1):61–4.CrossRef

90.

Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467–75.PubMedCrossRef

91.

Carrion F, Nova E, Ruiz C, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19(3):317–22.PubMedCrossRef

92.

van Laar JM, Farge D, Tyndall A. Autologous stem cell transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis. 2005;64(10):1515.PubMedCrossRef

93.

Craciunescu OI, Steffey BA, Kelsey CR, et al. Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplant trial. Int J Radiat Oncol Biol Phys. 2011;79(4):1248–55.PubMedCrossRef

Titel: An Update on Stem Cell Transplantation in Autoimmune Rheumatologic Disorders
verfasst von: Sheryl Mascarenhas
Belinda Avalos
Stacy P. Ardoin
Publikationsdatum: 01.12.2012
Verlag: Current Science Inc.
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 6/2012
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-012-0298-8

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

IgE-Mediated Cow’s Milk Allergy in Children

Cytokine Responses in the Common Cold and Otitis Media

Innovations in Technology: Social Media and Mobile Technology in the Care of Adolescents with Asthma

Cellular Targeting in Autoimmunity